3-Methylamino-1-methyl-4,5,6,7-tetrahydro-1H-indazol | 26396-86-1

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 3-Methylamino-1-methyl-4,5,6,7-tetrahydro-1H-indazol
• 英文别名: methyl-(1-methyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-amine；N,1-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-amine；N,1-dimethyl-4,5,6,7-tetrahydroindazol-3-amine
• CAS: 26396-86-1
• 化学式: C₉H₁₅N₃
• 分子量: 165.238
• InChiKey: VUHLDAOOIFPOKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS<br/>[FR] 1,4-OXAZEPINES CONDENSÉES ET LEURS ANALOGUES ASSOCIÉS EN TANT QU'INHIBITEURS DE BROMODOMAINE BET
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2017142881A1

  公开（公告）日：2017-08-24

  The present disclosure provides fused 1,4-oxazepines and related analogs represented by Formula (I) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, A, and Y are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a condition or disorder responsive to inhibition of BET bromodomains such as cancer.

  本发明公开了式(I)表示的融合1,4-噁嗪和相关类似物及其药学上可接受的盐、水合物和溶剂化物，其中R1、R2a、R2b、R3a、R3b、R4、R5、A和Y的定义如说明书中所述。本发明还涉及式(I)化合物用于治疗对BET溴结构域抑制有反应的病症或疾病，如癌症的用途。
• Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders
  申请人：Qiu Jun

  公开号：US20070231263A1

  公开（公告）日：2007-10-04

  The present invention relates to methods of identifying whether one or more candidate compounds is a modulator of a G protein-coupled receptor (GPCR) or a modulator of blood glucose concentration. In certain embodiments, the GPCR is human. The present invention also relates to methods of using a modulator of the GPCR. A preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for lowering blood glucose concentration, for preventing or treating certain metabolic disorders, such as insulin resistance, impaired glucose tolerance, and diabetes, and for preventing or treating a complication of an elevated blood glucose concentration, such as atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease.

  本发明涉及一种识别一个或多个候选化合物是否为G蛋白偶联受体（GPCR）的调节剂或血糖浓度的调节剂的方法。在某些实施例中，该GPCR为人类。本发明还涉及使用GPCR的调节剂的方法。首选的调节剂是激动剂。本发明的激动剂可用作治疗剂，用于降低血糖浓度，预防或治疗某些代谢性疾病，如胰岛素抵抗、糖耐量受损和糖尿病，以及预防或治疗血糖浓度升高的并发症，如动脉粥样硬化、心脏病、中风、高血压和外周血管疾病。
• Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders
  申请人：Qiu Jun

  公开号：US20080306114A1

  公开（公告）日：2008-12-11

  The present invention relates to methods of identifying whether one or more candidate compounds is a modulator of a G protein-coupled receptor (GPCR) or a modulator of blood glucose concentration. In certain embodiments, the GPCR is human. The present invention also relates to methods of using a modulator of the GPCR. A preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for lowering blood glucose concentration, for preventing or treating certain metabolic disorders, such as insulin resistance, impaired glucose tolerance, and diabetes, and for preventing or treating a complication of an elevated blood glucose concentration, such as atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease.

  本发明涉及一种识别一个或多个候选化合物是否为G蛋白偶联受体（GPCR）调节剂或血糖浓度调节剂的方法。在某些实施例中，GPCR是人类的。本发明还涉及使用GPCR调节剂的方法。首选的调节剂是激动剂。本发明的激动剂可用作降低血糖浓度的治疗剂，用于预防或治疗某些代谢性疾病，如胰岛素抵抗、糖耐量受损和糖尿病，以及预防或治疗血糖浓度升高的并发症，如动脉粥样硬化、心脏病、中风、高血压和周围血管疾病。